Dr. Flinn on Next Steps With Venetoclax Plus Obinutuzumab in CLL
In Partnership With:
Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses next steps with venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL).
Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses next steps with venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL).
Following the positive results of the phase Ib study, this combination is being evaluated in a phase III randomized trial in Germany. Flinn predicts that this trial will be positive, and demonstrate the viability of this option for this patient population.
